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Abstract
Metastasic breast cancer is the leading cause of death by malignancy in women worldwide. Tumor metastasis is a
multistep process encompassing local invasion of cancer cells at primary tumor site, intravasation into the blood
vessel, survival in systemic circulation, and extravasation across the endothelium to metastasize at a secondary site.
However, only a small percentage of circulating cancer cells initiate metastatic colonies. This fact, together with the
inaccessibility and structural complexity of target tissues has hampered the study of the later steps in cancer
metastasis. In addition, most data are derived from in vivo models where critical steps such as intravasation/
extravasation of human cancer cells are mediated by murine endothelial cells. Here, we developed a new mouse
model to study the molecular and cellular mechanisms underlying late steps of the metastatic cascade. We have
shown that a network of functional human blood vessels can be formed by co-implantation of human endothelial cells
and mesenchymal cells, embedded within a reconstituted basement membrane-like matrix and inoculated
subcutaneously into immunodeficient mice. The ability of circulating cancer cells to colonize these human
vascularized organoids was next assessed in an orthotopic model of human breast cancer by bioluminescent
imaging, molecular techniques and immunohistological analysis. We demonstrate that disseminated human breast
cancer cells efficiently colonize organoids containing a functional microvessel network composed of human
endothelial cells, connected to the mouse circulatory system. Human breast cancer cells could be clearly detected at
different stages of the metastatic process: initial arrest in the human microvasculature, extravasation, and growth into
avascular micrometastases. This new mouse model may help us to map the extravasation process with
unprecedented detail, opening the way for the identification of relevant targets for therapeutic intervention.
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Introduction
Metastatic disease is the main cause of death in breast
cancer patients [1]. Hematogenous cancer metastasis is a
multistep process encompassing local invasion of cancer cells
at primary tumors, intravasation into the blood vessel, survival
in systemic circulation, extravasation, colonization and
proliferation at the distant site, and ending with establishment
of growing metastatic lesions [2]. The reduced number of cells
involved at each step of the process along with the
inaccessibility of the relevant anatomical sites has hampered
the study of the mechanisms underlying metastasis. As breast
cancer usually metastasizes to organs such as liver, lung, bone
and brain, the ability to detect microfoci of cancer cells in an
experimental setting is hindered by difficulty in imaging cells in
these internal tissues [3]. In fact, most published studies have
focused on the initial steps of metastasis (local invasion and
intravasation) because they are more accessible for studying in
currently existing animal models [4].
The use of luminescent and fluorescent proteins and
developments in optical imaging technology are slowly
facilitating the study of the sequential metastatic process [5].
Whole body bioluminescence imaging enables the
dissemination of cancer cells through tissues to be monitored
longitudinally in the same animal (but with low spatial
resolution), whereas intravital microscopy (IVM), through
confocal or multiphoton imaging of tumors expressing
fluorescent proteins, enables spreading of a tumor to be
observed with subcellular resolution. However, such IVM
studies usually rely on dorsal skin chambers or reversible skins
flaps to increase sensitivity of detection and are therefore
limited to the primary tumor, providing only information over
initial steps of metastasis. Obviously, this technique is not
suitable for following tumor progression, and internal
metastasis in a live intact animal due to the invasiveness of the
procedure [5].
Consequently, the late steps in metastasis are poorly
understood. Therefore, clarifying the molecular and cellular
mechanisms underlying late steps of the metastatic cascade
(i.e. post-arrest events) is a major focus in cancer research. In
addition, all available experimental data are derived from in
vivo models where critical steps in hematogenous metastasis
of human cancer cells (intravasation and extravasation) are
mediated by murine endothelial cells.
Recently, we and others have demonstrated that a network
of functional human blood vessels can be formed in
immunodeficient mice by co-implantation of primary human
endothelial cells and human mesenchymal cells (MSC),
embedded within a reconstituted basement membrane-like
matrix [6-10]. Here, we demonstrate that BME-rich organoids
containing functional microvessels composed of human
endothelial cells support metastatic colonization in an
orthotopic model of breast cancer.
Materials and Methods
Ethics Statement
All experimental procedures were performed in accordance
with the Spanish Government guidelines for the care and use
of laboratory animals and were approved by the Hospital
Universitario Puerta de Hierro Animal Care and Use Committee
(CEBA).
Cells
MDA-MB-231 (human breast adenocarcinoma; HTB-26) cells
were obtained from the American Type Culture Collection
(Rockville, MD, USA) and were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat
inactivated FCS (all from Life Technologies, Gaithersburg, MD,
USA). Human Umbilical Vein Endothelial Cells (HUVEC) were
obtained from Lonza (Walkersville, MD, USA) and were
cultured in EGM-2 medium containing 2% fetal bovine serum
and endothelial cell growth supplements (Cambrex, Baltimore,
MD, USA). Human bone marrow-derived MSCs were obtained
from Inbiomed (San Sebastian, Spain) and cultured in low
glucose DMEM supplemented with 10% FCS of selected lots.
Lentiviral construction
An HIV-derived four-plasmid system was kindly provided by
D. Trono (Department of Microbiology and Molecular Medicine,
University of Geneva, Switzerland). The transfer vector pRRL-
IRES-EGFP contains a cytomegalovirus (CMV) promoter that
drives an enhanced-green fluorescent protein (EGFP)
expression cassette [11]. The plasmid pRRL-FLuc-IRES-EGFP
constructed as described previously [6], drives the expression
of the firefly luciferase (FLuc) reporter gene. To construct the
plasmid pRRL-RLuc-IRES-EGFP, the NheI/XbaI fragment
derived from the plasmid pRL-CMV (Promega, Madison, WI,
USA) was ligated into the XbaI digested backbone of plasmid
pRRL-IRES-EGFP. The plasmid pRRL-RLuc-IRES-EGFP drives
the expression of the renilla luciferase (RLuc) reporter gene.
Lentiviral particles were produced by co-transfection of 293T
cells through calcium phosphate precipitation, as described
[12].
Cell transduction
HUVEC passage 1 in normal growth media were seeded at a
density of 7.5 × 103 cells/cm2, allowed to adhere and infected
overnight with lentivirus (FLuc-IRES-EGFP) at a final multiplicity
of infection (MOI) of 10. HUVECFluc were used in vivo in
passages 3-5. MDA-MB-231 cells in normal growth media were
seeded at a density of 6.25 × 104 cells/cm2, allowed to adhere
and infected overnight with the lentivirus RLuc-IRES-EGFP at a
final MOI of 10.
Cell culture assays for luciferase activity
For bioluminescence imaging (BLI) of live intact cells
(HUVECFluc or MDA-MB-231Rluc), cell suspensions were serially
diluted into appropriate cell culture media in 96-well plates
(ranging from 6400 to 100 cells/well) and analyzed in triplicate.
After the addition of 20 µg/well of the appropriate substrate (D-
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Luciferin or coelenterazine; Promega), bioluminescence was
quantified using an Infinite 200 microplate luminometer (Tecan,
Switzerland).
Endothelial cell proliferation assay
Endothelial cell proliferation assay was performed by
seeding HUVEC or HUVECFluc (500 cells/well) in 96-well plates
in complete HUVEC medium. After 24 hours the cells were
switched to fresh EBM-2 basal medium with 0.1% FCS and
incubated for 24 hours, then the cells were switched to fresh
EBM-2 with 0.5% FCS in the absence or presence of 20 ng/mL
of VEGF (Peprotech, London, UK). The cells were cultured for
an additional 48 hours, and viable cells were detected using
the MTT colorimetric assay (Sigma-Aldrich, St. Louis, MO,
USA).
Endothelial cell tube formation assay
Basement Membrane Extract (BME) (Matrigel, BD
Biosciences) was plated at 4 °C in 96-well plates, and allowed
to gellify for 30 min at 37 °C, then HUVEC or HUVECFluc in 1%
EGM-2 medium, were plated (1.5 x 104 cells/well) and cultured
for 14-16 hours. Formation of capillary-like structures was
assessed by bright-field and fluorescence microscopy.
Flow cytometry
For phenotypic analysis cells were treated with appropriate
dilutions of fluorochrome-conjugated mAbs (Table S1) for 30
min at 4 °C. All samples were fixed in 2% formaldehyde and
analyzed with a Beckman-Coulter FC-500 Analyzer (Beckman
Coulter, Fullerton, California, USA).
Animal studies
Six-week-old female athymic nude mice (Hsd: athymic Nude/
Nude; Harlan Ibérica, Barcelona, Spain) were used for
abdominal wall implantation and for xenograft experiments.
Mice were kept under anesthesia during all manipulations and
all efforts were made to minimize suffering. Anesthesia was
induced in an induction chamber with 2.5% isofluorane in 100%
oxygen at a flow rate of 1 L/min and maintained with a 1.5%
mixture at 0.5 L/min. Animals were housed under pathogen-
free conditions and were given irradiated food and autoclaved
water ad libitum. For abdominal implantation of human BME-
rich vascularized organoid (HVO) a mixture (ratio 4:1) of
HUVECFluc (3 x 105) and MSC (7.5 x 104), were suspended in
150 µl BME (Matrigel) and inoculated subcutaneously in the
ventral area (right lower quadrant). For abdominal implantation
of BME-rich control organoids (CO) 150 µl of Matrigel were
inoculated subcutaneously in the ventral area (left lower
quadrant). All batches of Matrigel were adjusted to 8 mg/ml by
addition of PBS and supplemented with heparin (128 U/ml)
(Sigma-Aldrich), human VEGF (50 ng/ml) and human bFGF
(150 ng/ml) (both from PeproTech). MDA-MB231Rluc cells (2 x
106) were injected directly into the second left mammary fat
pad of each mouse, 48 hours after abdominal wall HVO
implantation. Tumor growth and metastasis spread was
monitored every week by RLuc BLI for up to 10 weeks. Tumors
were measured twice weekly using precision calipers. Tumor
volume was calculated using the formula: width2 x length x
0.52. The functionality of HVO was monitored every two weeks
by FLuc BLI up to 10 weeks.
In vivo and ex vivo bioluminescence imaging
Mice were imaged using the high-resolution charge-coupled-
device (CCD) cooled digital camera ORCA-2BT (Hamamatsu
Photonics France, Massy, France), and Hokawo software
(Hamamatsu Photonics). The mice were anesthetized using
inhaled isoflurane, as described above, injected i.v. with 125
mg/kg (100 µl) D-luciferin dissolved in PBS or with 900 mg/kg
(100 µl) coelenterazine-based compound dissolved in PBS,
and placed on a thermostated bed. BLI was collected with 1
min integration time in FLuc imaging and with 5 min integration
time in RLuc imaging and pseudocolor representations of light
intensity were superimposed over the grayscale reference
image acquired at low light (exposure time 20 ms). An average
of 6 kinetic BLI acquisitions was collected after substrate
injection to confirm a peak of photon emission. For quantitation
of the detected light, regions of interest were drawn and the
light emitted from each region was recorded by recording the
total number of photons per second (total flux) after
background subtraction. At the end of each experiment
anesthetized animals were sacrificed and BME-rich organoids
(CO and HVO), inguinal lymph node and the different organs
(lung, liver and spleen) were rapidly harvested and processed.
Organs and BME-rich organoids were placed in PBS
containing coelenterazine-based compound and individually
and immediately scanned for the presence of RLuc
bioluminescent metastatic cells during 1 min of integration time
as described above.
RNA isolation and real-time quantitative PCR
Total RNA isolation of tumor and organs was performed
using the RNeasy Plus Mini Kit (Qiagen GmbH, Hilden,
Germany) or the RNeasy Plus Micro Kit (Qiagen) according to
the weight of the sample used for the RNA extraction. For
disruption and homogenization of samples, MagNA Lyser
Green Beads (Roche Diagnostics, IN, USA) were used
according to the manufacturer’s protocol. cDNA was
synthesized using 0.1 mg of total RNA by random primed
reverse transcription with SuperScript VILO cDNA Synthesis kit
for RT–PCR (Roche Applied Science, Germany) according to
the recommended protocol. Real-time quantitative PCR (RT-
qPCR) was performed in a LightCycler 480 apparatus (Roche
Applied Science) using the LightCycler 480 SYBR Green I
Master kit (Roche Applied Science). mRNA expression in each
sample was measured as a ratio against the geometric
average of the reference housekeeping human gene succinate
dehydrogenase complex subunit A (SDHA). The relative
concentrations of the target and the reference genes were
calculated by interpolation using a standard curve of each gene
plotted from the same serial dilution of cDNA. PCR primers
(Table S2) were designed with Primer Express software
(Applied Biosystems, Foster City, CA, USA) or Universal
ProbeLibrary Assay Design Center (Roche Applied Science).
The resulting amplicons had a size of approximately 100 pb.
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Immunohistochemistry
Immunohistochemical analyses were performed on 5 µm
formalin-fixed, paraffin-embedded tissue sections. Briefly,
samples were deparaffinized, re-hydrated and subjected to
antigen retrieval procedures as described previously [12]. A
histological section from each initial tissue specimen was
stained with hematoxylin and eosin according to standard
protocols. The mAbs used are listed in Table S3. Primary
mouse mAbs were detected with the Mouse on Mouse
(M.O.M.) peroxidase kit (Vector Laboratories, Burlingame, CA,
USA). Primary rat mAbs were detected with the Vectastain®
ABC kit for rat IgG (Vector Laboratories). As a chromogenic
substrate, DAB (Vector Laboratories) was used, followed by
hematoxylin counterstaining. Staining was evaluated using
Leica DM E microscope (Leica Microsystems, Jena, Germany).
Images were acquired using Leica ICC50 HD camera and
processed by Leica LAS EZ software. The number of CD45+
cells was evaluated quantitatively in four randomly chosen
areas of BME-rich organoids (CO and HVO).
Quantitative analyses of vascular morphogenesis
Vascular structures in BME-rich organoids (HVO and CO)
were classified as either immature or mature vessels. Mature
vessels were defined as vessel structures containing
erythrocytes. Vascular morphogenesis was quantified by
enumerating the mature vessels in four randomly chosen fields
and expressing the mean ± SD obtained for each condition. In
order to assess vascular leakiness, extravascular red blood
cells (RBC) were quantified in four randomly chosen fields and
mean ± SD obtained for each organoid type is shown.
Extravascular RBC are those erythrocytes localized inside the
organoids but unrelated to vascular structures.
Immunofluorescence
Immunofluorescence analysis was performed on formalin-
fixed paraffin-embedded 3 µm tissue sections. After
deparaffinization, heat antigen retrieval was performed in pH
9.0 EDTA-based buffer. Human CD44 was detected using the
rabbit mAb clone EPR1013Y (Table S3) and an Alexa Fluor
655 conjugated goat anti-rabbit IgG antibody (Molecular
Probes, Life Technologies). Human CD34 was detected using
the mouse mAb clone QBEnd10 (Table S3), and an Alexa fluor
488 conjugated goat anti-mouse IgG antibody. Sections were
counterstained with DAPI (Abbott Molecular, Abbott, Park, IL,
USA) to visualize cell nuclei. Fluorescence assays were
performed at room temperature using a Dako Autostainer
(Dako, Carpinteria, CA, USA). Staining was evaluated by two
investigators (F.R. and S.Z.) using a Leica fluorescence
DM2000 microscope and images were obtained and processed
by Nuance FX Multispectral Imaging System (CRi, Caliper,
Hopkinton, MA, USA).
Statistics
The mean and standard deviation (SD) were calculated by
using Prism V (Graphpad Software, San Diego, CA, USA), and
error bars represent the SD. Each experiment was performed a
minimum of three times. The data were evaluated by t test and
were considered to be statistically significant when p <0.05.
Results
Establishment and histological analysis of human
vascularized organoids
Confirming our previous work [6,10] we found that the co-
implantation of genetically modified human umbilical vein
endothelial cells (HUVEC) harboring the firefly luciferase (FLuc)
gene (HUVECFLuc) and human bone marrow derived MSC
(Figure S1-S4) embedded within a reconstituted basement
membrane extract (BME, also known as Matrigel)
supplemented with VEGF, bFGF and heparin and inoculated
subcutaneously into nude mice (Figure 1a), results in the
formation of mature, stable human blood vessels. These
vessels are functional, meaning that they are able to
anastomose with preexisting mouse vessels, and can be
assessed non-invasively and quantitatively by in vivo
bioluminescent imaging (BLI) (Figure 1b). The temporal
silencing of luciferase activity and subsequent recovery is
related to the lapse of time required for the establishment of an
incipient vascular network and its integration into the mouse
vascular bed [6].
In this paper we performed a detailed histological
characterization of the implants. The injection of 150 µl of
supplemented BME containing HUVECFLuc and MSC, originated
the formation of very stable organoids (Figure 1a), with
volumes ranging from 13.7 to 25.5 mm3. The mean was 19.8 ±
5.1 (SD). Two main areas can be distinguished: a central
homogeneous region, with an extensive network of perfused
blood vessels (containing erythrocytes; Figure 1c arrowheads)
and few non-vascular cells, and a peripheral region with
appreciable adipogenesis [13], in close contact with the
subcutaneous tissue of the host (Figure 1c). The network of
capillary-like microvessels with a clear endothelial lining that
expressed human CD34, was distributed rather uniformly
throughout the organoid, while murine vessels were distributed
almost exclusively in the periphery of the organoid and the
surrounding host tissues (Figure 2). Interestingly, some human
blood vessels constituted poorly organized vascular structures
that mimic renal glomeruli (Figure 1c, arrow). These structures
have been named as “glomeruloid microvascular
proliferations”, and represent a type of angiogenic blood vessel
[14]. The human vascularized BME-rich organoids (HVO) were
well tolerated by the host and did not evoke adverse
inflammatory responses. A weak inflammatory infiltrate (Figure
S5) constituted mainly by macrophages and neutrophils was
present in the periphery of the organoid (Figure 2), whereas B
lymphocytes, NK cells and cells from other hematopoietic
lineages were not present (data not shown). Finally, interstitial
cells showed a myofibroblast phenotype [vimentin and α-
smooth muscle actin (SMA)], and were interspersed in the
organoid (Figure 2). Furthermore, with the exception of an
increase in vascular density, and adipocyte size and number
(Figure S6), the general structure of the organoid and the
amount of infiltrating cells were unchanged for more than 60
days (Figure S7).
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As shown in Figure 3, the subcutaneous implantation of 150
µl of supplemented BME alone resulted in the formation of
organoids with a volume similar to HVO (average volume 17.6
± 1.6 mm3). However, control organoids (CO) without human
cells (HUVECFLuc and MSC) were pale, indicating no or little
blood vessel formation (Figure 3a). Histological analysis
confirmed that the CO were colonized by murine cells but the
degree of vascularization (neo-vessel density and complexity)
was significantly lower than that observed in HVO (p < 0.05,
Figure S8a). By contrast vascular leakiness, quantitatively
assessed by counting the number of extravascular
erythrocytes, was significantly higher in CO (p < 0.05, Figure
S8b and c) than in HVO. A marked adipogenesis was observed
in all areas of the CO sections (Figure 3b).
Immunohistochemical staining demonstrated that the
peripheral region exhibited a dense CD34 positive vascular
network that contains luminal vessels filled with erytrocytes
(Figure 3b arrowheads), and a weak inflammatory infiltrate
(Figure 4) similar to that observed in HVO (Figure S5).
Human vascularized organoids are colonized more
efficiently by disseminated human breast cancer cells
than control organoids
The ability of circulating cancer cells to colonize HVO and
CO was next assessed in an orthotopic model of human breast
cancer. Implantation of MDA-MB-231 human breast cancer
cells into the second left mammary fat pad (MFP) of 6-8 weeks
old female athymic nude mice is a well-characterized
spontaneous metastasis model [15,16]. The take-rate
percentage of genetically modified MDA-MB-231 cells
expressing the renilla luciferase (RLuc) gene (MDA-MB-231RLuc)
(Figure S1-S2) in the MFP orthotopic xenograft model was
Figure 1.  Generation of BME-rich organoids with functional human blood vessels in immunodeficient mice.  (a) A mixture
of HUVECFLuc (3 x 105) and human MSC (7.5 x 104) were embedded in supplemented BME (150 µl) and inoculated subcutaneously
in the ventral area (right lower quadrant) of immunodeficient mice. Human vascularized BME-rich organoids were easily identified as
small bumps under the skin at all times in vivo. (b) Ventral D-luciferin-based FLuc-BLI images of a representative mouse 1, 2, 4, 7, 10
and 13 weeks after implantation of the human vascularized BME-rich organoid. (c) Low magnification (4x) micrograph displaying the
entire organoid (Scale bar is 1 mm). Hematoxylin and eosin (H and E)-stained sections taken from different part of the organoids
revealed the presence of numerous luminal structures containing erythrocytes (arrowheads), and some glomeruloid microvascular
proliferations (arrows). 10x and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g001
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Figure 2.  Immunohistochemical characterization of human vascularized BME-rich organoids.  Immunohistochemical
characterization of explanted human vascularized BME-rich organoids using anti-CD34 (species specific: human and mouse; [39]),
anti-CD45, anti-F4/80, anti-neutrophils, anti-vimentin and anti-α-SMA antibodies (Table S3). Cell nuclei were counterstained with
hematoxylin. 10x and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g002
A New Mouse Model to Study Cancer Metastasis
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80% (n = 10), and the growth kinetics was examined over the
subsequent 6–10 weeks (Figure 5a). Mice were evaluated for
primary tumor growth (caliper method and in vivo BLI), HVO
functionality and spontaneous metastasis (in vivo and ex vivo
BLI).
MDA-MB-231RLuc mammary tumor bioluminescence started
to increase about 3 weeks after tumor cell injection (Figure 5b,
upper panels). Metastatic signals also appeared at that time in
the left axillary region in 33% of the mice, indicating
spontaneous ipsilateral thoracic metastasis. Subsequent
thoracic images demonstrated a progressive increase in
metastatic spread over time, and by week 6 half of the animals
had developed bilateral thoracic metastases, visible by in vivo
BLI (Figure 5b). By 7–10 weeks, metastatic signals appeared in
the inguinal region in 50% of the mice. HVO remained
functional throughout the study period (Figure 5b, lower
panels).
Representative ex vivo images are shown in Figure 5c. As
shown in Figure 5d metastases were detected in lungs,
inguinal lymph nodes and HVO in all mice (n = 8). By contrast
only a third of CO were colonized, while no metastases were
detected in the liver or spleen. Figure 5e shows quantification
of light emission by excised tissues. The metastatic burden
was significantly higher in inguinal lymph node and lungs that
in HVO. However, HVO ex vivo signals were significantly
higher than those observed in the CO (p < 0.001). Subsequent
histological evaluation confirmed extensive metastases through
the lung tissue. To determine which antibody was best suited to
define the metastatic deposits, we performed
immunohistochemical studies with anti-CD44 and anti-RLuc
antibodies. MDA-MB-231RLuc cells expressed high levels of
CD44 respectively on the cell surface (Figure S9a), whereas
RLuc was found in the cytoplasm (Figure S9b). Our results
indicate that the anti-CD44 mAb provides the best definition of
the metastatic breast cancer cells, and allows the identification
of metastases of varying sizes (Figure S9c).
Figure 3.  Generation of control BME-rich organoids without human cells in immunodeficient mice.  (a) Supplemented BME
(150 μl) was inoculated subcutaneously in the ventral area (left lower quadrant) of immunodeficient mice. Control BME-rich
organoids were easily identified as small bumps under the skin at all times in vivo. (b) Low magnification (4x) micrograph displaying
the entire organoid (Scale bar is 1 mm). Hematoxylin and eosin (H and E)-stained sections taken from different part of the control
organoids revealed the presence of numerous adipocytes, and some luminal structures containing erythrocytes (arrowheads). 10x
and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g003
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Figure 4.  Immunohistochemical characterization of control BME-rich organoids.  Immunohistochemical characterization of
explanted control BME-rich organoids using anti-CD34 (species specific: human and mouse; [39]), anti-CD45, anti-neutrophils, anti-
vimentin and anti-α-SMA antibodies (Table S3). Cell nuclei were counterstained with hematoxylin. 10x and 40x images are shown.
doi: 10.1371/journal.pone.0072957.g004
A New Mouse Model to Study Cancer Metastasis
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Molecular detection and characterization of
disseminated tumor cells and micrometastases in
human vascularized organoids
The presence of MDA-MB-231RLuc cells in the lungs and
HVOs was assessed as a function of RLuc expression relative to
human succinate dehydrogenase A (SDHA). RLuc and SDHA
mRNA levels were quantified by quantitative reverse
transcription-PCR. In both cases RLuc mRNA concentrations
were well correlated (r = 0.82 and 0.85, respectively) with ex
vivo bioluminescence (Figure 6).
To further confirm the presence of MDA-MB-231RLuc cells in
the HVOs, and to study their distribution, we performed
immunofluorescence studies in those HVO with the highest ex
vivo bioluminescence emission (n = 3). As shown in Figure 7a,
randomly distributed isolated or small clusters (mean = 3.1 ±
1.7 SD) of tumor cells were detected through the HVO inside
the human CD34+ microvessels. These intravascular CD44+
cells were either circulating, attached to the endothelium or
trapped in the capillary-like microvessels. Notably some of the
intravascular MDA-MB-231RLuc cells traversed the human
vascular wall to colonize the surrounding matrix (Figure 7a).
Moreover, in addition to these micrometastases we identified
larger growing metastases, composed by 40-50 CD44+ tumor
cells adjacent to blood vessels of human origin (Figure 7b).
Discussion
We have herein described a new mouse model to study
metastatic colonization, and we demonstrate that disseminated
human breast cancer cells efficiently colonize BME-rich
organoids containing a functional microvessel network
composed of human endothelial cells connected to the mouse
Figure 5.  Spontaneous metastasis from primary mammary fat pad tumors.  MDA-MB-231RLuc human breast cancer cells were
implanted into the orthotopic environment of the left axillary MFP of nude mice bearing human vascularized BME-rich organoids
(HVO) and control BME-rich organoids (CO), without human cells. Primary tumor growth (a, b), metastatic spread (b-e) and HVO
functionality (b, c) were monitored over time in vivo and ex vivo. (a) Tumor growth curves for MDA-MB-231RLuc (n = 10) orthotopic
mammary tumors. (b) In vivo ventral coelenterazine-based RLuc-BLI images (upper panels) and D-luciferin-based FLuc-BLI images
(lower panels) of a representative mouse. (c) Ex vivo coelenterazine-based RLuc-BLI images (upper panels) and D-luciferin-based
FLuc-BLI images (lower panels) of excised lungs, inguinal lymph node (LN), spleen, liver, HVO and CO of a representative mouse.
(d) Percentage of metastatic colonization and (e) tumor burden in harvested tissues (normal mouse organs and BME-rich
organoids) of mice (n = 8) with primary tumor growth. Significant differences (*** p < 0.001).
doi: 10.1371/journal.pone.0072957.g005
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circulatory system. Despite their apparent structural simplicity,
HVO were efficiently colonized by MDA-MB-231 cells, and
importantly, human breast cancer cells could be unequivocally
detected at different stages of the metastatic process: initial cell
arrest in human capillaries, extravasation, and growth from
avascular micrometastases to vascularized micrometastases
growing into the surrounding BME. In control BME-rich
organoids without human cells, the number of vessels was
lower than in the HVO and these were more immature and
leaky. Despite increased leakiness of vessels in CO, the
percentage of metastatic colonization was significantly lower
than that observed in HVO, although we cannot rule out that
differences in microvascular density may contribute to
differences in the number of metastasis.
Tumor-derived BME has been used for more than 20 years
in models (both in vitro and in vivo) of angiogenesis, invasion
and primary tumor growth [15-17]. Proteomics analysis of
tumor-derived BME resulted in the identification of 1302 unique
proteins [20], but in fact it is composed mainly of laminin-111
(56%), collagen IV (31%), entactin (8%) and perlecan (4%)
Figure 6.  Correlation between mRNA levels of Renilla Luciferase (RLuc) and ex vivo coelenterazine-based RLuc-
bioluminescence of lungs (n = 4) and human vascularized BME-rich organoids (n = 5).  In both cases RLuc mRNA
concentrations were well correlated (a: r = 0.829; b: r = 0.851) with ex vivo bioluminescence data.
doi: 10.1371/journal.pone.0072957.g006
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[21]. These components constitute what has been called the
“basement membrane toolkit” [22], which is found in most
metazoans and has been shown to be crucial to their evolution.
Given that the basement membrane is the first extracellular
matrix (ECM) produced in the developing embryo, it was
quickly identified as an important factor for modulating stem
cell behavior [23], that plays multiple roles in the stem cell
niche. It is perhaps not surprising then that BME is the gold
standard for the maintenance of a wide array of human
embryonic stem cell (hESC) lines, as it contains all of the
proteins that have been shown to promote hESC growth when
used individually [24].
Furthermore, increasing evidence suggests that the ECM is
also a key component of the cancer stem cell niche [25]. In
fact, the ECM not only promotes cancer cell growth at the
primary site but also provide signals that support metastatic cell
survival, colonization and proliferation [25]. Several reports
have recently revealed that the ECM proteins fibronectin,
tenascin-C, periostin and versican play essential roles as
components of the metastatic niche for tumor-initiating cells
that invade the lungs [25–29]. Not surprisingly, BME has been
widely used to test the metastatic potential of cancer cells in
vitro [18].
During the past several years, a crucial role for bone-marrow
derived cells in priming distant tissues for tumor engraftment
has been uncovered [26]. VEGFR1+ hematopoietic progenitor
cells are mobilized and recruited early during the formation of
pre-metastatic niche [26]. A causal relationship between
Figure 7.  Detection of disseminated tumor cells in human vascularized BME-rich organoids.  sections. (a) The parenchyma
contains a network of human CD34+ capillary-like microvessels (in green) and numerous isolated or clusters of CD44+ MDA-MB-231
tumor cells (in red), which are circulating (white arrow), attached to the endothelium (yellow arrow) or extravasating and colonizing
the surrounding matrix (asterisk). (b) Small foci of CD44+ MDA-MB-231 tumor cells adjacent to human CD34+ capillary-like
microvessels and glomeruloid microvascular proliferations. Nuclei are labeled in DAPI, x200. Scale bar is 25 μm.
doi: 10.1371/journal.pone.0072957.g007
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chronic inflammation and metastasis formation has been
proposed [30], and accordingly a variety of inflammatory cells
(CD11b+ myelod cells, monocytes/macrophages, lymphocytes
and neutrophils) that drive primary tumor growth may have an
important role in metastatic colonization [31,32]. In addition
stromal cells [33,34] and endothelial cells [35,36] also
participate in the metastatic niche. Although we have not
studied the contribution of host-derived cells in the colonization
of HVO, this model could be an ideal system for studying the
role of different cell types in the process of metastatic
colonization.
Molecular interactions between human breast cancer cells
and murine endothelial cells may not recapitulate those taking
place during intravasation and extravasation of cancer cells in
patients. For this reason, we estimate that mice carrying
human vascularized BME-rich organoids would be a more
suitable model for studying the interactions between
disseminated cancer cells and host endothelium. In fact, a
murine microenvironment is not always a “congenial soil” for
metastatic human cells [37]. For example, in a mouse model of
human breast cancer, bone metastases were more frequent
when the target organ was of human origin, suggesting a
species-specific tropism [38].
In summary, we have described here the generation and
characterization of a simple, non-invasive mouse model that
could more accurately recapitulate human breast cancer
metastasis, and could be easily adapted for intravital
microscopy. Although this model is still artificial, it may help to
assess the cancer cell extravasation step in a more
physiological setting than previous models, opening new
avenues to the development of innovative anti-cancer
strategies.
Supporting Information
Figure S1.  Schematic representation of lentiviral
bicistronic vectors. Schematic representation of the lentiviral
bicistronic vectors pRRL-FLuc-IRES-EGFP containing firefly
luciferase (FLuc) and enhanced-green fluorescent protein
(EGFP) genes (a), and pRRL-RLuc-IRES-EGFP containing
renilla luciferase (RLuc) and EGFP genes (b). LTR, long terminal
repeat; ΔGAG, ATG-deleted group-specific antigen; RRE, Rev-
responsive element; EMCV IRES, encephalomyocarditis virus
internal ribosomal entry site.
(TIF)
Figure S2.  EGFP expression and bioluminescent
properties of HUVECFLuc and MDA-MB-231RLuc cells. Flow
cytometry analysis showing EGFP expression by lentivirally
transduced HUVECFLuc (a) or MDA-MB-231RLuc (c) cells.
Bioluminescent properties of HUVECFLuc (b) or MDA-
MB-231RLuc cells (d) in the presence and absence of substrate
(D-luciferin or coelenterazine). Luciferase activity is expressed
as relative light units (RLU). Data represent the average ± SD
of triplicate samples.
(TIF)
Figure S3.  Comparative study of wild-type HUVEC and
lentivirally transduced HUVECFLuc. Flow cytometry alaysis of
CD34 or CD31 expression (Table S1) on HUVEC (a) and
HUVECFLuc (b). Isotype-matched antibodies were used as
control (grey line). VEGF significantly induced HUVEC (c) and
HUVECFLuc (d) proliferation. Data represent the mean ± SD of
triplicate samples. The differences were statistically significant
(*p < 0.05, **p < 0.01). Formation of capillary-like structures by
HUVEC (e) and HUVECFLuc (f) cultured for 14-16 h on
reconstituted Matrigel.
(TIF)
Figure S4.  Phenotype of bone marrow-derived human
MSC. Cells were trypsinized, labeled with antibodies against
the indicated antigens (Table S1) and analyzed by flow
cytometry. Isotype-matched antibodies were used as control
(grey line).
(TIF)
Figure S5.  Comparative analysis of CD45+ cells in human
vascularized and control BME-rich organoids.
Mean ± SD of cells stained with anti-CD45 antibody (Table S3)
in four randomly chosen fields (n = 3).
(TIF)
Figure S6.  Temporal changes in mature vessel density
and in the total adipocyte number in human vascularized
BME-rich organoids. Temporal changes in mature vessel
density (mean ± SD of perfused vessels in four randomly
chosen fields, n = 3) (a), and the number of adipocytes per
square millimeter (mean ± SD, n = 3) (b).
(TIF)
Figure S7.  Hematoxylin and eosin-stained sections of
human vascularized BME-rich organoids. 15 days (a), 30
days (b), and 45 days after implantation. 4x and 10x images
are shown.
(TIF)
Figure S8.  Comparative analysis of mature vessel density
and vascular leakiness in human vascularized and control
BME-rich organoids 30 days after implantation. (a) Mean ±
SD of perfused vessels in four randomly chosen fields (n = 3).
(b) Mean ± SD of extravascular red blood cells (RBC) in four
randomly chosen fields (n = 3). Significant differences (* p <
0.05). (c) Hematoxylin and eosin-stained sections and
immunohystochemical characterization of explanted BME-rich
human vascularized and control organoids using anti-CD34
(species specific: human and mouse [39]).
(TIF)
Figure S9.  Characterization of antibodies against CD44
and Renilla Luciferase (RLuc). (a) Cell surface expression of
CD44 (MEM-85) in MDA-MB-231RLuc cells. (b-c)
Immunohistochemical staining of lung metastases. Serial
sections of lung tissue were stained for CD44 (F10-44-2) and
RLuc. 10x and 40x images are shown.
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(TIF)
Table S1.  Fluorochrome-conjugated monoclonal
antibodies.
(DOCX)
Table S2.  Primer pairs used for real-time quantitative RT-
PCR.
(DOCX)
Table S3.  Unconjugated monoclonal antibodies.
(DOCX)
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